Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out
March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

MEBO survey for Dr Hazen click here
Read more/less

Regular readers will know that Dr Stan Hazen et al at Cleveland Clinic are developing a TMA-blocker pill, as they proposed in a 2011 paper that TMAO is a factor in CVD. Recently Dr Hazen and colleagues contacted MEBO as they have always thought they could also help with TMAU. This survey is to give them an idea of the 'state of the community'. It is a "version 1". They may not even look (though they have access permission), but it could be useful to give them an overview of the community

MEBO had a zoom call with Dr Hazen and his team in October. Another zoom call is planned when they have time

MEBO Research Clinical Trials

Sunday, November 29, 2020

UK lab blocks TMA formation from CARNITINE

The 2 main sources of Trimethylamine in humans (via diet) seem to be (not much research) bacterial enzyme degradation of diet CHOLINE and CARNITINE. 

Choline degradation seems to be the main source, say 80-90% ?? (pure guess).

The upcoming Cleveland / Procter & Gamble tma-blocker pill looks to mainly block the choline path (though we don't know really. Maybe it blocks both?).

Now a (small) UK Uni lab (University of Warwick) which looks at bacterial enzymes has blocked bacterial degradation of Carnitine to TMA.

Bacterial enzymes :
Bacteria (and archeae etc) have enzymes that can break things down.
In relation to TMA formation in the human gut, there seems to be 2 enzymes that can break down TMA precursors :
cut-C enzyme for Choline to TMA ?
and now this lab says CntA enzyme for Carnitine to TMA.

So the lab seems to have blocked CntA enzymes from breaking down Carnitine.

It seems they are at the first stage, and a long way from producing a carnitine-TMA blocker pill (if ever). Including the need for funding (not got money on tap like Cleveland Clinic).

It's also unknown how big an impact a carnitine-tma blocker pill would have, as most of the TMA seems to be from choline pathway.

The lead researchers write in an email :

"Thank you for your email regarding our recent work on the Carnitine to TMA formation pathway.

Yes, this work complements the Choline pathway in that we have a crystal structure model of the carnitine degrading “CntA” enzyme with a better understanding of how carnitine is recognised by the enzyme. And yes, the inhibitors we report are the first of their kind against CntA.  

We envisage, this work establishes a strong platform to progress the research to improve the inhibitors. We are eagerly awaiting to hear if we have been successful in securing follow up funding to progress this work. We’d be looking to test the inhibitors against a wider range of bacteria representative of the gut microbiome and demonstrate that we can indeed inhibit carnitine breakdown with such inhibitors in the gut microbiome. We’d also like to further develop the inhibitors for potency and improved efficacy against the bacteria responsible. Ideally, a combo Carnitine + Choline blocker therapeutic would be the ultimate realisation to treat TMAU in the long run.  

Thank you once again for reaching out, it is a pleasure to know our work is noticed and appreciated; reinforcing our research motivations."

Structural basis of carnitine monooxygenase CntA substrate specificity, inhibition and inter-subunit electron transfer
Mussa Quareshy1, Muralidharan Shanmugam2, Eleanor Townsend3, Eleanor Jameson3, Timothy D.H. Bugg4, Alexander D Cameron3 and Yin Chen3
1School of Life Sciences, University of Warwick, United Kingdom
2University of Manchester, United Kingdom
3University of Warwick, United Kingdom
4Department of Chemistry, University of Warwick, United Kingdom

get New Posts by EMAIL : Enter your email address :

A EURORDIS and NORD Member Organization

Sunday, November 15, 2020

Freedom from Shame

In July 2019, our MEBO Mental Health Director, Crissan Rosalia, Health Psychologist, MSC. and Coach, wrote a paper for the MEBO community, 'Breaking the patterns of shame.' in which she expounds in a very clear and easy to follow manner on how shame and guilt can shape our lives in a very adverse manner. Her analysis of this process depicts how they can create a negative self-image, create feelings of powerlessness, worthlessness and isolation.

In this new paper, Crissan tells of a personal journey, inviting us to look at our own lives, as she has her own, to identify how shame creeps in and the immense impact it has had on the way we see self, others, and our place in the world. Reading this new paper on Freedom from Shame' invites the reader to go into an active personal journey of self-exploration and to continue the journey towards self-healing. The meditations Crissan provides shows us the way to personal healing towards freedom of shame.




Thank you, Crissan, for this opportunity to pursue inner healing and happiness.

for all of Crissan's posts.


María de la Torre
Founder and Executive Director

A Public Charity
MEBO's Blog (English)
El Blog de MEBO (español)

Click Amazon button at right sidebar of this blog when shopping online
for the holidays
at no extra cost to you.
MEBO gets small commission from Amazon.

get New Posts by EMAIL : Enter your email address :

A EURORDIS and NORD Member Organization

Tuesday, November 10, 2020

Survey for potential TMAU therapeutic research database

Click on icon for full paper

The aim of this Survey is to collect information to create a database that may be used for future research of a TMAU therapeutic. Everyone around the world in the MEBO community, RareConnect Trimethylamine community, and anyone who has been diagnosed with Trimethylaminuria (TMAU) or suffer from uncontrollable odor conditions yet to be diagnosed are welcome to submit their answers to this Survey.

Your personal information will be kept confidential throughout the study, and the researcher team will only receive a MEBO ID Number that will be assigned to you. In the event that another researcher with another research study is looking for participants, your answers in this survey will not be disclosed without your prior stated consent and permission.

This survey is the work of MEBO RESEARCH, a patient advocacy 501(c)(3) Public Charity registered in the State of Florida, and a Not For Profit, Limited By Guarantee Company registered in England and Wales.

Thank you for your contribution to this initiative.


María de la Torre
Founder and Executive Director

A Public Charity
MEBO's Blog (English)
El Blog de MEBO (español)

Click Amazon button at right sidebar of this blog
when shopping online for the holidays
at no extra cost to you.
MEBO gets small commission from Amazon.

get New Posts by EMAIL : Enter your email address :

A EURORDIS and NORD Member Organization